The Translational Genomics Research Institute (TGen), part of City of Hope, today announced the launch of JAYseqTM, a ...
The funeral ceremony was not attended by any mourners.
Despite significant improvements in survival of patients with multiple myeloma (MM), outcomes remain heterogeneous, and a significant proportion of patients experience suboptimal outcomes. Importantly ...
Primary endpoint met at the interim analysis in MagnetisMM-5 trial demonstrating a statistically significant and clinically meaningful improvement in progression-free survival Safety was consistent ...
Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 MagnetisMM-5 study evaluating ELREXFIO ® (elranatamab) as monotherapy in adults with relapsed or refractory multiple ...
Angus Chen covers all issues broadly related to cancer including drugs, policy, science, and equity. He joined STAT in 2021 after covering health and science at NPR and NPR affiliate stations. His ...
Daratumumab (DARA) + bortezomib/lenalidomide/dexamethasone (VRd) in transplant-eligible (TE) patients (pts) with newly diagnosed multiple myeloma (NDMM): Analysis of ...
Third-wave feminists have set women back 50 years. Just look what they’ve done to women’s sports. Their forebears in the movement would be appalled. Once the promises of voting and property rights had ...
Around 1,600 people a year in England with multiple myeloma are set to benefit from a new treatment option after we recommended belantamab mafodotin (also known as Blenrep and made by GSK). Our ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results